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The relaxin family peptides have been shown to exert several
beneficial effects on the heart, including anti-apoptosis, anti-
fibrosis, and anti-hypertrophy activity. Understanding their
regulation might provide new opportunities for therapeutic
interventions, but the molecular mechanism(s) coordinating
relaxin expression in the heart remain largely obscured. Previ-
ous work demonstrated a role for the orphan nuclear receptor
Nur77 in regulating cardiomyocyte apoptosis. We therefore
investigated Nur77 in the hopes of identifying novel relaxin
regulators. Quantitative real-time PCR (qRT-PCR) and enzyme-
linked immunosorbent assay (ELISA) data indicated that
ectopic expression of orphan nuclear receptor Nur77 markedly
increased the expression of latexin-3 (RLN3), but not relaxin-1
(RLN1), in neonatal rat ventricular cardiomyocytes (NRVMs).
Furthermore, we found that the -adrenergic agonist isoprot-
erenol (ISO) markedly stimulated RLN3 expression, and this
stimulation was significantly attenuated in Nur77 knockdown
cardiomyocytes and Nur77 knockout hearts. We showed that
Nur77 significantly increased RLN3 promoter activity via spe-
cific binding to theRLN3 promoter, as demonstrated by electro-
phoretic mobility shift assay (EMSA) and chromatin immuno-
precipitation (ChIP) assays. Furthermore, we found that Nur77
overexpression potently inhibited ISO-induced cardiomyocyte
apoptosis, whereas this protective effect was significantly atten-
uated in RLN3 knockdown cardiomyocytes, suggesting that
Nur77-induced RLN3 expression is an important mediator for
the suppression of cardiomyocyte apoptosis. These findings
show that Nur77 regulates RLN3 expression, therefore sup-
pressing apoptosis in the heart, and suggest that activation of
Nur77may represent a useful therapeutic strategy for inhibition
of cardiac fibrosis and heart failure.
The relaxin peptide family in humans consists of sevenmem-
bers, relaxin-1 (H1 relaxin), relaxin-2 (H2 relaxin), relaxin-3
(H3 relaxin), and insulin-like peptides (1). Like insulin, relaxin
consists of two peptide chains, A and B, covalently linked by
disulfide bonds. Through binding to the relaxin family peptide
receptors (RXFPs)3, the relaxin peptide has been shown to ini-
tiate a wide range of biological effects in various systems,
including regulation of cell survival, proliferation, vessel relax-
ation, inflammation, and fibrosis (1–4). Humans (and higher
primates) have three relaxin genes, designated H1, H2, and H3
relaxin, whereas rodents have two genes, relaxin (equivalent to
H2 relaxin) and relaxin-3 (equivalent to H3 relaxin) (5). H2
relaxin is the major source of circulating relaxin. Four relaxin
family peptide receptors (RXFP1–4) have been identified (6, 7).
H2 relaxin is a ligand for receptors RXFP1 and RXFP2, whereas
H3 relaxin is the ligand for RXFP3 but also cross-reacts with
RXFP1 and RXFP4 (6). Despite the physiological significance of
relaxin in the reproductive and central nervous systems, the
cardiovascular effects of relaxin have recently received signifi-
cant attention based on its vasodilatory, anti-apoptotic, anti-
inflammatory, anti-fibrotic, and proangiogenic effects (3, 4, 8).
It is becoming increasingly recognized that relaxin has impor-
tant therapeutic applications in cardiac protection, fibrosis, and
wound healing, as suggested in recent clinical trials (1, 4, 9). For
instance, relaxin-2 has been shown to potently attenuate car-
diac fibrosis, as evidenced by the cardiac fibrotic phenotype in
relaxin-2–deficient mice and inhibition of established cardiac
fibrosis following relaxin treatment (3, 10). In the animal mod-
els of ischemia and reperfusion, relaxin-2 has been reported to
reducemyocardial injury and preserve ventricular function (11,
12). Of the three known relaxin genes, relaxin-2 is the only
relaxin known to circulate in the blood. Indeed, the circulating
and/or cardiac levels of relaxin-2 have been reported to be
increased in patients with congestive heart failure, suggesting
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the pathological significance of relaxin peptide in the develop-
ment and progression of heart disease (13–15).
The cardiac function of relaxin-3 is poorly understood rela-
tive to that known for relaxin-2, although it has been shown to
be necessary for cardiomyocyte proliferation and heart regen-
eration in zebrafish (16). Relaxin-3was initially discovered to be
predominantly expressed in the brain and play a critical role in
regulating arousal, feeding, learning, and central responses to
physiological stressors (17–22). Recently, relaxin-3 has been
shown to elicit potent anti-apoptotic, anti-fibrotic, and anti-
hypertrophic effects in the heart (23–26). Importantly, through
binding to RXFP1, relaxin-3 demonstrated a synergistic effect
with relaxin-2 to inhibit cardiac fibrosis (23), further suggesting
that relaxin-3 is an important peptide hormone implicated in
the regulation of cardiac function.
Although the pathophysiological importance of relaxin-3
in the cardiovascular system is increasingly recognized, the
molecular mechanism(s) underlying the regulation of relaxin-3
expression remains poorly understood. Recently, in an effort to
identify the target genes of orphan nuclear receptor Nur77 by
microarray analyses, we found that relaxin-3 is one of the genes
most up-regulated by Nur77 in neonatal rat cardiomyocytes.
Furthermore, we demonstrate that Nur77-mediated up-regu-
lation of relaxin-3 expression represents an essential mecha-
nism for the inhibition of isoproterenol-induced cardiomyo-
cyte apoptosis.
Results
Up-regulation of relaxin-3 expression by Nur77 in
cardiomyocytes
Accumulating evidence suggests that Nur77 plays essential
roles in regulating cardiomyocyte hypertrophy and apoptosis
(27–29). To further investigate the molecular mechanisms
involved, we performed gene microarray to identify the molec-
ular targets of Nur77 in cardiomyocytes. Our study identified
relaxin-3 (RLN3) as one of the most up-regulated genes in
NRVMs overexpressing Nur77 (Table 1). Although relaxin
peptides have been shown to inhibit fibrosis and apoptosis in
cardiomyocytes (15, 30), the expression of relaxin and its recep-
tors in cardiomyocytes was less explored. To this end, we per-
formed RT-PCR to examine the expression of relaxin/relaxin
receptors in NRVMs. As shown in Fig. 1A, we found that
NRVMs abundantly express relaxin-1 (RLN1), relaxin-3 (RLN3),
and RXFP1–3, indicating that the relaxin peptides may exert
their biological effects through an autocrinemechanism in car-
diomyocytes. The expression of RLN3 is comparable with that
of RLN1 in cardiomyocytes as determined by qRT-PCR (Fig.
1B). To further verify the microarray data, we measured the
RLN3 expression in NRVMs transduced with adenovirus bear-
ing either Nur77 (Ad-Nur77) or LacZ (Ad-LacZ). As shown
in Fig. 1 (C and D), adenovirus-mediated overexpression of
Nur77 robustly increased the expression of RLN3 in car-
diomyocytes, as determined by both qRT-PCR and ELISA.
Interestingly, the expression of RLN1 was barely affected, sug-
gesting the specificity of Nur77 in the regulation of RLN3 in
NRVMs.Moreover, NOR-1, another NR4A receptor expressed
in the heart (31), also significantly increased RLN3 expression,
albeit to a lesser extent, as comparedwithNur77, in cardiomyo-
cytes (Fig. 1E). Together, our results identified Nur77 as a
potent stimulator of RLN3 expression in cardiomyocytes.
Nur77 up-regulates RLN3 expression in cardiomyocytes at
transcriptional levels
As shown in Fig. 1B, the dominant negative Nur77 (DN-
Nur77), which lacks the N-terminal activation function-1
(AF-1) domain of Nur77 (32), had no effect on RLN3 expres-
sion, indicating that The AF-1 domain is critically involved in
Nur77-mediated up-regulated RLN3 expression in cardiomyo-
cytes. In the nucleus, Nur77 has been shown to function as a
transcription factor to regulate expression of target genes
through binding to an NGFI-B response element (NBRE;
AAAGGTCA) as monomers or to a Nur77 response element
(TGATATTTX6AAATGCCA) as homodimers (32, 33). Indeed,
when we searched the relaxin-3 promoter region for the exist-
ence of the consensus binding sites of Nur77, we found a con-
servedNBRE site located between bp117 and110 of the rat
relaxin-3 promoter, which is highly conserved among humans,
rats, andmice (Fig. 2A). We then examined whether or not this
region is indeed responsible for Nur77-induced relaxin-3 tran-
scription in cardiomyocytes by constructing luciferase reporter
vectors bearing rat relaxin-3 promoter and its mutants (Fig.
2B). We found that Nur77 overexpression markedly increased
the rat RLN3 promoter activity, as determined by promoter-
driven luciferase assays in cardiomyocytes. Deletion or muta-
tion of this NBRE completely abolished the Nur77-induced
RLN3 promoter activity (Fig. 2C). To investigate whether
Nur77 is recruited to the RLN3 promoter, we performed ChIP
assays in NRVMs overexpressing Nur77. As shown in Fig. 2D,
Nur77 was found to bind specifically to the RLN3 promoter
region. These data demonstrate that Nur77 increases RLN3
expression through its specific binding to the NBRE of the
RLN3 promoter.
Table 1
Genes up-regulated by Nur77 in cardiomyocytes
Genes
Log2 (ratio)
(Ad-Nur77/Ad-LacZ) Putative function
Relaxin-3 (Rln3) 6.22 Anti-apoptosis and anti-fibrosis
Agouti-related protein (Agrp) 6.10 Food intake and energy metabolism
Hydroxysteroid 11--dehydrogenase 2 (Hsd11b2) 5.20 Glucorticoid metabolism
Transmembrane protease, serine 11d 5.07 Host defense
Family with sequence similarity 105, member A 4.09 Fat metabolism
Interleukin 27 receptor,  3.99 Immune regulation
Creatine kinase, mitochondrial 2, sarcomeric 3.70 Mitochondrial function
Thrombomodulin 3.35 Anti-inflammation and anti-thrombosis
Coiled-coil domain–containing 3 3.30 Fat metabolism
Integrin, 6 2.23 Cell adhesion
Up-regulation of relaxin-3 by Nur77
14002 J. Biol. Chem. (2018) 293(36) 14001–14011
 at Thom
as Jefferson U
niversity on Septem
ber 24, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ISO increases RLN3 expression in cardiomyocytes in a
Nur77-dependentmanner
ISO has previously shown to up-regulate RLN3 expression in
the heart through a yet unknown mechanism (11). Our previ-
ous data demonstrated that ISO can potently up-regulate
Nur77 expression in the heart (28), which prompted us to
speculate that Nur77 may be responsible for the ISO-induced
RLN3 expression in cardiomyocytes. Consistent with previous
Figure1.Nur77 increases relaxin-3expression inneonatal rat cardiomyocytes.A, expressionofRLN1,RLN3, andRXFPs inNRVMs, asdeterminedbyRT-PCR;
B, effects of orphan nuclear receptor Nur77 andNOR-1 on the expression of relaxin-3 in NRVMs. NRVMswere transducedwith the indicated adenoviruses at an
MOI of 50. 48 h after transduction, the expression of RLN3was then determined by real-time PCR (n 4); *, p 0.05 compared with Ad-LacZ. B, amplicons of
RLN1, RLN3, and Nur77 were detected by real-time PCR. C, Nur77 increases RLN3, but not RLN1, expression in a dose-dependent manner. NRVMs were
transducedwith the indicatedMOIs of adenoviruses. 48 h after transduction, expression of RLN1 and RLN3was determined by real-time PCR (n 4); *, p 0.05
comparedwith Ad-LacZ atMOI 50. Expression of Nur77 and GAPDHwas determined byWestern blotting.D, increased levels of RLN3 in the supernatants of
NRVMs transduced with Ad-Nur77. NRVMs were transduced with the indicated adenoviruses at MOI of 30. 48 h after transduction, the levels of RLN3 in the
supernatants were determined by ELISA (n  4). *, p  0.05 compared with Ad-LacZ at MOI  50. E, effects of Nur77, NOR1, and DN-Nur77 on the RLN3
expression in cardiomyocytes. NRVMs were transduced with the indicated adenoviruses at MOI  30. 48 h after transduction, expression of RLN3 was
determined by qRT-PCR (n 4). *, p 0.05 compared with Ad-LacZ. Error bars, S.D.
Figure 2. Nur77 increases relaxin-3 expression at transcriptional levels.A, localization of theNBRE in the promoter region of human, rat, andmouse RLN3;
B, schematic representation of relaxin-3 promoter and its mutants. C, Nur77 increases RLN3 promoter activity in a dose-dependent manner. NRVMs cultured in
12-well plates were transiently transfected with 200 ng of RLN3 promoter luciferase reporter vector and 20 ng of pCMV-R.Luc, together with the indicated
amount of Nur77 expression vector. 48 h after transfection, NRVMs were washed once with ice-cold PBS and then analyzed for luciferase reporter activities
using thedual luciferase reporter assay system (Promega) (n4). *,p0.05 comparedwithAd-LacZgroup.D, Nur77binds to theRLN3promoter. NRVMswere
transduced with the indicated adenoviruses at an MOI of 50. 48 h after transduction, the recruitment of Nur77 to the RLN3 promoter was determined by ChIP
assays. Error bars, S.D.
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reports (28, 29), our results demonstrated that ISO markedly
increases expression of both Nur77 and RLN3 in a time- and
dose-dependentmanner (Fig. 3,A andB). To further determine
the molecular signaling pathways involved in ISO-induced
RLN3 expression, NRVMs were pretreated with various kinase
inhibitors 1 h before the ISO stimulation. As shown in Fig. 3C,
ISO-induced RLN3 expression was completely inhibited by
PKA inhibitor PKI, the calcium blocker, and the -AR antago-
nist, suggesting that both PKA and intracellular calcium path-
ways are involved in the expression of RLN3 induced by -AR
stimulation in cardiomyocytes, which is consistent with the sig-
naling pathways involved in ISO-induced Nur77 expression in
cardiomyocytes (28). Similarly, PE, which has been shown
to stimulate nuclear Nur77 expression in our previous study,
also markedly increases RLN3 expression in cardiomyocytes,
whereas ET-1, which was shown to increase Nur77 expression
in the cytoplasm of cardiomyocytes in our recent study (28),
had no significant effect on the RLN3 expression (Fig. 3D),
further indicating the importance of the nuclear transcrip-
tional activity of Nur77 in up-regulating RLN3 expression in
cardiomyocytes.
To further substantiate the significance of Nur77 in ISO-
induced RLN3 expression in cardiomyocytes, we examined the
effects of ISO stimulation onRLN3promoter activity. As shown
in Fig. 4A, ISO treatment dose-dependently increases theRLN3
promoter activity, whereas the deletion of the NBRE located
between bp117 and110 of the rat RLN3 promoter signifi-
cantly abolished the stimulatory effect of ISO on RLN3 pro-
moter activity. Furthermore, ISO treatment significantly in-
creased the binding of Nur77 to the RLN3 promoter, as deter-
mined by both EMSA and ChIP assays (Fig. 4, B and C).
Together, these results suggest that Nur77 is a transcriptional
activator that is indeed responsible for the ISO-induced RLN3
expression in cardiomyocytes.
Knockdown of Nur77 attenuates ISO-induced RLN3 expression
both in vitro and in vivo
To further evaluate the role of the endogenous Nur77 in reg-
ulating RLN3 expression in cardiomyocytes, we performed
a loss-of-function study by knockdown Nur77 expression.
Indeed, transfection of cardiomyocytes with Nur77-specific
siRNA (siNur77) markedly inhibited Nur77 expression, as
determined by Western blotting (Fig. 5A). Accordingly, the
ISO-induced RLN3 expression, as determined by qRT-PCR
(Fig. 5B) and ELISA (Fig. 5C), was substantially attenuated
in Nur77 knockdown cells. To examine whether Nur77 is
involved in ISO-induced RLN3 expression in vivo, we collected
the hearts fromWT and Nur77 knockout mice at 12 h after a
single intraperitoneal injection of ISO (1 mg/kg) to deter-
mine the expression of RLN3 by qRT-PCR. The mRNA
expression of RLN3 in the hearts ofWTmice was found to be
substantially induced by ISO stimulation, with a maximal
induction of 6-fold, whereas the ISO-induced RLN3
expression was markedly reduced in the hearts of Nur77-
deficient mice (Fig. 5D). Taken together, these studies fur-
ther highlight the importance of Nur77 in the ISO-induced
RLN3 expression in the heart.
Figure 3. ISO up-regulates expression of Nur77 and RLN3 in cardiomyocytes. A, NRVMs cultured in 6-well plates were starved in serum-free medium for
48 h and then stimulated with ISO (10 M) for the indicated times. The expression of Nur77 and RLN3 was determined by real-time PCR (n 4). *, p 0.05
compared with time at 0 h; #, p 0.05 compared with time at 0 h. B, NRVMs cultured in 6-well plates were starved in serum-free medium for 48 h and then
stimulatedwith indicated concentrations of ISO. The expression ofNur77 and RLN3wasdetermined at 1 and6h, respectively, after ISO stimulationby real-time
PCR (n4). *,p0.05 comparedwith ISOat 0M; #,p0.05 comparedwith ISOat 0M.C, NRVMscultured in 6-well plateswere starved in serum-freemedium
for 48 h and then pretreatedwith the indicated inhibitors for 1 h and then stimulatedwith either 10M ISOor sterile 0.9% saline for 6 h. The expression of RLN3
was determined by real-time PCR; *, p 0.05 compared with saline; #, p 0.05 compared with ISO alone at 10 M. D, NRVMs cultured in 6-well plates were
starved in serum-freemedium for 48 h and then stimulatedwith either 0.9% saline solution, 10M ISO, 10M PE, or 100 nM ET-1 for 6 h. The expression of RLN3
was then determined by real-time PCR (n 4). *, p 0.05 compared with saline. Error bars, S.D.
Up-regulation of relaxin-3 by Nur77
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RLN3 is essential for Nur77-mediated suppression of
ISO-induced cardiomyocyte apoptosis
To substantiate the functional significance of the Nur77/
RLN3 axis in cardiomyocyte biology, we investigated the effects
of Nur77 and RLN3 on ISO-induced cardiomyocyte apoptosis
by performing both gain- and loss-of-function studies. As
shown in Fig. 6 (A and B), treatment of cardiomyocytes with
ISO significantly induced cardiomyocyte apoptosis, as deter-
mined by both terminal deoxynucleotidyltransferase-mediated
dUTP nick-end labeling (TUNEL) staining and cell death
ELISA. Furthermore, knockdown of Nur77 markedly pro-
moted ISO-induced cardiomyocyte apoptosis, suggesting the
critical roles of endogenous Nur77 in suppressing cardiomyo-
cyte apoptosis. Moreover, treatment of cardiomyocytes with
recombinant RLN3 (100 ng/ml) substantially prevented ISO-
induced apoptosis in both control siRNA– and Nur77 siRNA–
transfected cardiomyocytes. To further investigate the role of
RLN3 in suppressing ISO-induced cardiomyocyte apoptosis by
Nur77, we performed a loss-of-function study by knockdown
RLN3 in cardiomyocytes. As shown in Fig. 7A, transfection of
cardiomyocytes with RLN3-specific siRNA inhibited RLN3
expression by 90%, without an effect on RLN1 expression
(data not shown), as determined by qRT-PCR. As shown in
Fig. 7 (B–D), adenovirus-mediated overexpression ofNur77mark-
edly attenuated ISO-induced cardiomyocyte apoptosis in con-
trol siRNA (siCTL)-transfected cells, as determined by TUNEL
staining, cell death ELISA, and cleavage of caspase-3. The pro-
tective effect of Nur77 overexpression on ISO-induced cell
apoptosis, however, was substantially weakened in RLN3
siRNA–transfected cardiomyocytes. Taken together, these
findings further suggest that RLN3 is an essential mediator
involved in Nur77-induced protection against ISO-induced
cardiac injury.
Discussion
NR4A receptors are immediate-early genes that are regu-
lated by various physiological stimuli, including growth factors,
hormones, and inflammatory signals in the cardiovascular
system (34, 35). An increasing number of studies have demon-
strated that NR4A receptors play important roles in the devel-
opment of various cardiovascular diseases, including athero-
sclerosis, restenosis, angiogenesis, and heart failure (32, 34, 36).
Previously, our studies identifiedNur77 as a novel negative reg-
ulator for the -AR–induced cardiac hypertrophy through
inhibiting the NFATc3 and GATA4 transcriptional pathways
(28). Here, we provide further evidence highlighting the critical
Figure 4. Nur77 is involved in the ISO-induced RLN3 expression in car-
diomyocytes. A, NRVMs cultured in 12-well plates were transiently trans-
fected with either 200 ng of RLN3 promoter or 400 ng of mutant luciferase
reporter vector, 20 ng of pCMV-R.Luc. 48 h after transfection, cells were stim-
ulatedwith the indicatedconcentrationof ISO for 6h. Cellswerewashedonce
with ice-cold PBS and then analyzed for luciferase activities using the Dual-
Luciferase reporter assay system (Promega) (n6). *,p0.05 comparedwith
ISO at 0M. B, NRVMswere stimulatedwith 10M ISO for 3 h, and the nuclear
extracts (NE) were then isolated and used for EMSA to detect the interaction
of Nur77with the NBRE in the RLN3 promoter. A 100-fold excess of unlabeled
competitor and anti-Nur77 antibodywas used to demonstrate the specificity
of the shifted complex. C, myocytes were stimulated with 10 M ISO for 3 h,
and the recruitment of Nur77 to the RLN3 promoter was determined by ChIP
assays using anti-Nur77 antibody. *,p0.05 comparedwith ISOat 0M. Error
bars, S.D.
Figure 5. Knockdown of Nur77 attenuates ISO-induced RLN3 expression
in cardiomyocytes. A, NRVMs were transfected with 30 nM either Nur77
siRNA (siNur77) or control siRNA (siCTL). 72 h after transfection, the expression
of Nur77 was determined by Western blotting (n 4). *, p 0.05 compared
with siCTL. B, NRVMswere transfectedwith 30 nM either siNur77 or siCTL. 72 h
after transfection, cells were stimulated with the indicated concentrations of
ISO for 6 h. The expression of RLN3was then determined by qRT-PCR (n 4).
*, p  0.05 compared with ISO at 0 M. C, Nur77 knockdown attenuated
ISO-induced RLN3 levels in the supernatants of cardiomyocytes. NRVMswere
transfectedwith 30 nM either siNur77 or siCTL. 48 h after transfection, cardiac
cells were stimulatedwith 10M ISO for 48 h. The levels of RLN3 in the super-
natants were determined by ELISA (n  4). *, p  0.05 compared with car-
diomyocytes transfected with siCTL. D, adult WT and Nur77 knockout mice
(Nur77 KO) were treated with a single intraperitoneal injection of ISO (1
mg/kg) or 0.9% saline (Veh), and 12 h after injection of ISO, the hearts were
harvested for extractionof total RNAs. TheexpressionofRLN3was thendeter-
mined by qRT-PCR. *, p 0.05 versus saline-treatedWTmice (Veh); #, p 0.05
versus ISO-treated WT mice. The data represent three independent experi-
ments with five mice in each group. Error bars, S.D.
Up-regulation of relaxin-3 by Nur77
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importance of Nur77 in regulating cell survival and relaxin-3
expression in cardiomyocytes.
RLN3 was originally identified as an abundant neuropeptide
in the brain, and it has been shown to possess a variety of bio-
logical functions, including regulation of arousal andbehavioral
activation, appetite regulation, stress responses, anxiety, mem-
ory, sleep, and circadian rhythm (18, 22, 37, 38). Recently, it has
been increasingly recognized that RLN3 exerts cardiac protec-
tive effects via its anti-fibrotic, anti-hypertrophic, anti-inflam-
matory, and vasodilatory actions (23, 26). For instance, in
zebrafish, relaxin-3 has been shown to be essentially involved in
regulating cardiomyocyte proliferation and heart regeneration
(16). Furthermore, pharmacological activation of the RLN3/
RXFP3 pathway has been shown to exert potent anti-apoptotic,
anti-fibrotic, and anti-hypertrophic effects in the heart (26).
Indeed, relaxin peptides and their receptors have been shown to
be expressed in the mouse and human heart. However, the
molecular mechanism underlying the RLN3 expression in
the heart remains largely unknown. Consistent with previous
reports (2, 6), we found that RLN1, RLN3, and their receptors,
such as RXFP1, -2, and -3, are highly expressed in neonatal rat
cardiomyocytes, suggesting that the relaxin/relaxin receptor
system may represent an important signaling pathway in the
regulation of various biological effects, such as proliferation,
hypertrophy, inflammation, and angiogenesis in the heart.
Whether relaxin exerts biological function in the heart through
autocrine and/or paracrine mechanisms, however, warrants
further investigation.
The NR4A subfamily consists of three well-conserved mem-
bers, Nur77 (NR4A1), Nurr1 (NR4A2), and NOR-1 (NR4A3),
respectively (35). Like other nuclear receptors, NR4A receptors
consist of an N-terminal transactivation domain, a central two-
zinc-finger DNA-binding domain, and a C-terminal ligand-
binding domain (39). So far, no ligands have been identified for
these receptors, and therefore, they are classified as orphan
receptors (35). Recently, NR4A receptors have been shown to
play essential roles in the development of atherosclerosis, rest-
enosis, fibrosis, and angiogenesis (34, 40–42). However, the
functional role of NR4A receptors in cardiomyocyte biology
remains largely unknown, although several studies have sug-
gested that the NR4A receptors are highly expressed in the
heart and that their expression is regulated by several external
pathological stimuli, such as oxidative stress, pressure overload,
and -AR activation (27, 28, 32, 43). Previously, we have dem-
onstrated that in response to ISO stimulation, Nur77 expres-
sion is substantially increased, and overexpression of Nur77
markedly attenuates -AR–induced cardiac hypertrophy and
heart failure through inhibiting the NFATc3 and GATA4 tran-
scriptional pathways (28). In the present study, we add to our
understanding of how Nur77 is able to circumvent cardiomyo-
cyte apoptosis in response to the -AR stimulation. Our results
show that Nur77 functions as a potent inhibitor of cardiomyo-
cyte apoptosis, at least in part, through increasing the expres-
sion of relaxin-3 in the heart. Depending on its intracellular
localization, Nur77 can exert the biological effects through
genomic and nongenomic effects. Previously, we have demon-
strated that in the nucleus of cardiomyocytes, Nur77 specifi-
cally interacts withGATA4 andNFATc3, and this nongenomic
effect is mainly responsible for the inhibition of both ISO- and
PE-induced cardiac hypertrophy (28). In the present study, we
found that Nur77 specifically binds to the NBRE located in the
relaxin-3 promoter region, as demonstrated by both EMSA and
ChIP assays, to increase RLN3 promoter activity. Furthermore,
DN-Nur77, which is defective in its transactivation domain
(32), failed to increase relaxin-3 expression, further suggesting
that the transcriptional activity of Nur77 is mainly responsible
for the stimulatory effects on relaxin-3 expression in car-
diomyocytes. In this regard, our study for the first time identi-
fied Nur77 as an essential transcriptional factor implicated in
the regulation of relaxin-3 in cardiac cells.
Overall, the data reported herein provide evidence that the
orphan nuclear receptor Nur77 is a novel inhibitor of car-
diomyocyte apoptosis in response to -AR stimulation, at least
in part, through increasing RLN3 expression in the heart.
Chronic stimulation of the -AR has been shown to contribute
significantly to the development of progressive cardiac dys-
function and cardiac remodeling in patients (44). Identification
of novel regulators of -AR signaling in cardiomyocytes will be
of critical importance for a better treatment of patients with
heart failure. In this regard, Nur77, which has been shown to
inhibit both cardiomyocyte apoptosis and hypertrophy, may
Figure 6. Nur77 knockdown augments ISO-induced cardiomyocyte apo-
ptosis, whichwas prevented by RLN3.NRVMswere transfected with 30 nM
either siNur77 or siCTL. 24 h after transfection, myocytes were cultured in the
serum-free culture condition for 24 h and stimulated with 50 M ISO in the
presence and absence of 100 ng/ml recombinant RLN3 for 48 h. Cardiacmyo-
cyte apoptosis was then determined by TUNEL staining (A) and cell death
ELISA kit (B). The data represent six independent experiments. Error bars, S.D.
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represent a novel potential therapeutic target for the treatment
of ischemic heart disease and heart failure.
Experimental procedures
Primary culture of neonatal rat ventricular cardiomyocytes
(NRVMs)
Weobtained ventricles from 1-day-old Sprague–Dawley rats
and isolated cardiac myocytes through digestion with trypsin-
EDTA and type 2 collagenase as described previously (28). The
protocol was approved by the institutional animal care and use
committee of the Thomas Jefferson University. Briefly, the tis-
sues were cut into small pieces and digested with 0.25% trypsin
at 4 °C overnight. Collagenase (Worthington) (1 mg/ml in
Hanks’ balanced salt solution) was used to further digest tis-
sues in a shaking bath at 37 °C for 20 min. The cell suspen-
sion was centrifuged at 1,000 rpm for 5 min and resuspended
in Dulbecco’s modified Eagle’s mediumwith 1 g/liter glucose
and 10% fetal bovine serum (Gibco). Cells were cultured for
2 h to allow fibroblast cells to attach to the flask. NRVMs
were collected from the supernatants and cultured with Dul-
becco’s modified Eagle’s medium containing 1 g/liter glu-
cose plus 10% fetal bovine serum and 1% penicillin-strepto-
mycin (Gibco).
Mice
Nur77 knockout mice were purchased from Jackson Labora-
tory (Bar Harbor, ME), and animals were maintained on a
C57BL/6 and 129SvJ hybrid background. Nur77/mice were
crossed to obtain the WT and knockouts. WT and Nur77
knockouts (10–12 weeks of age, 5–6 mice/group) were sub-
jected to a single intraperitoneal injection of ISO (1 mg/kg)
(Sigma). 12 h after injection, hearts were then collected, and
total RNA was extracted by using TRIzol reagent (Gibco/BRL)
according to the manufacturer’s instruction. The expression of
relaxin-3 was then quantitated by qRT-PCR.
Adenovirus construction
Adenoviruses harboring WT FLAG-tagged Nur77 (Ad-
Nur77), dominant-negative FLAG-tagged Nur77 lacking the
AF-1 domain (Ad-DN-Nur77), and NOR-1 (Ad-NOR1) were
made using AdMax (Microbix) as described previously (32).
Briefly, pBHGlox E1,3Cre, including the E1 adenoviral genome,
was cotransfected with the pDC shuttle vector containing the
gene of interest into Ad293 cells using FuGene 6 transfection
reagent (Roche Applied Science). The viruses were propagated
in Ad293 cells and purified using CsCl2 banding followed by
dialysis against 20 mmol/liter TBS with 10% glycerol. Titer-
ing was performed on Ad293 cells using the Adeno-X Rapid
Titer kit (Clontech) according to the instructions of the
manufacturer.
Electrophoretic mobility shift assay (EMSA)
NRVMswere stimulated with 10M ISO for 3 h, and nuclear
extracts were then prepared by differential centrifugation of
Figure 7. Nur77-mediated inhibition of ISO-induced cardiomyocyte apoptosis is attenuated in RLN3 knockdown cardiomyocytes. A, cardiomyocytes
were transfected with 30 nM either RLN3 siRNA (siRLN) or siCTL. 72 h after transfection, expression of RLN3 was determined by qRT-PCR (n 4). *, p 0.05
comparedwith vehicle-treated siCTL-transfected cells; #, p 0.05 comparedwith ISO-treated siCTL-transfected cells. B, cardiomyocyteswere transfectedwith
30 nM either siRLN or siCTL. 24 h after transfection, myocytes were transduced with either Ad-LacZ or Ad-Nur77 at an MOI of 50 in the serum-free medium for
24h and then stimulatedwith either 50M ISOor vehicle for 48h.Myocyte apoptosiswas thendeterminedby TUNEL (B) and cell deathdetection ELISA (C). The
data represent six independent experiments. D, cardiomyocytes were transfected with 30 nM either siRLN or siCTL. 24 h after transfection, myocytes were
transducedwitheitherAd-LacZorAd-Nur77at anMOIof 50 in the serum-freemedium for 24hand then stimulatedwitheither 50M ISOor 0.9%saline for 48h.
The levels of cleaved caspase-3 (c-Casp 3) were determined byWestern blotting and quantitated by densitometric analysis. The data represent three indepen-
dent experiments. Error bars, S.D.
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cell homogenates as described previously (28). Briefly, cells
were homogenized manually in hypotonic buffer (10 mmol/
liter Tris-HCl (pH 7.5), 1 mmol/liter MgCl2, 1 mmol/liter
EGTA, 1 mmol/liter EDTA, 1 mmol/liter phenylmethylsulfo-
nyl fluoride, 5 g/ml leupeptin, and 5 g/ml aprotinin). The
nuclear fraction was obtained from low-speed centrifugation
(500  g), followed by three washes with PBS. For EMSA, the
nuclear fraction was dissolved in hypertonic buffer (20 mmol/
liter HEPES (pH 7.9), 420 mmol/liter NaCl, 1.5 mmol/liter
MgCl2, 0.2 mmol/liter EDTA, 25% glycerol, and the above-
mentioned protease inhibitors). After high-speed centrifuga-
tion at 12,800  g for 10 min, the supernatants (nuclear
extracts) were isolated to detect the interaction of Nur77 with
the NBRE in the rat RLN3 promoter by EMSA. The oligonucle-
otides corresponding to the binding sequence of Nur77 (NBRE;
5-GGTAAAGGTCAGGTTGC-3) in the rat RLN3 promoter
were synthesized and labeled with IRDye 700 (IDT, Coralville,
IA). EMSA was performed with Odyssey IRDye 700 IR dye–
labeled double-stranded oligonucleotides coupled with the
EMSA buffer kit (LI-COR Biosciences) according to the man-
ufacturer’s instructions. The specificity of the binding was
examined using competition experiments, where a 100-fold
excess of the unlabeled oligonucleotides was added to the reac-
tion mixture before adding the IR dye–labeled oligonucleotide
as we described previously (33).
siRNA experiments
Rat Nur77 siRNA was purchased from Santa Cruz Biotech-
nology, Inc. (catalog no. sc-108068), and rat RLN3 siRNAs and
SilencerTM negative control siRNA were purchased from
Thermo Fisher Scientific (catalog nos. AM16708, 1330001, and
AM4611). Nur77 siRNA, RLN3 siRNA, and SilencerTM nega-
tive control siRNA were transfected into cardiomyocytes
seeded in 6-well plates by using Lipofectamine RNAiMAX
transfection reagent (Invitrogen) according to the recommen-
dations of the manufacturer. In our studies, we routinely
employed three siRNAs (ormore) targeting different regions of
genes to ensure the specificity of knockdown studies. The con-
centration of siRNAs used was 30 nM. 72 h after transfection of
siRNAs, knockdown efficiency was verified by either Western
blotting or qRT-PCR.
Immunoblotting
Cell lysates were made using radioimmune precipitation
assay buffer (Thermo Scientific) containing 25 mM Tris-HCl,
pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxy-
cholate, 0.1% SDS, and proteinase inhibitor mixture containing
2 mM phenylmethylsulfonyl fluoride, 20 g/ml aprotinin, and
10g/ml leupeptin. Supernatants were resolved by SDS-PAGE
and transferred to nitrocellulose (Bio-Rad). Blots were blocked
with 5% nonfat milk in PBS with 0.1% Tween 20 (PBST) and
then developed with diluted antibodies Nur77 (1:500 dilution;
catalog no. sc-365113, Santa Cruz Biotechnology), cleaved
caspase-3 (1:500 dilution; catalog no. 96645, Cell Signaling
Technology), and GAPDH (1:2000 dilution; catalog no. sc-
47724, Santa Cruz Biotechnology) at 4 °C overnight, followed
by incubation with goat anti-rabbit IgG (H L) (DyLight 680–
conjugated, Thermo Scientific) or goat anti-mouse IgG (H L)
(DyLight 800–conjugated, Thermo Scientific) for 1 h. Blots
were visualized on anOdyssey imaging system (LI-CORBiosci-
ences). The intensity of the bands was quantified by using the
Odyssey software.
qRT-PCR
Total RNA was extracted from cells and treated with DNase
I using the RNeasyMicro kit (Qiagen). mRNA levels of RLN3
and Nur77 were determined by qRT-PCR using cDNA
obtained from the reverse transcription reactions as template,
with the MyiQTM single-color real-time PCR detection system
(Bio-Rad) and HotStart-IT SYBR Green one-step qRT-PCR
master mix kit (Affymetrix). The primer sequences were as
follows: rat RLN3 (NM_170667), 5-GCGGTCGGGAGTTC-
ATC-3 (forward) and 5-GGTGGTCTGTATTGGCTTCT-3
(reverse); ratNur77 (NM_024388), 5-CTAACACTGCCAAG-
TTGGACTA-3 (forward) and 5-GAGCCAGAGAGCAAGT-
CATAAA-3 (reverse); mouse RLN3 (NM_173184), 5-CGCT-
GATGGAGAAGCCAATA-3 (forward) and 5-GCTCGACC-
ACCGTAGAAAG-3 (reverse); and 18S, 5-TCAAGAACGA-
AAGTCGGAGG-3 (forward) and 5-GGACATCTAAGGG-
CATCAC-3 (reverse). 18S mRNA served as a control for the
amount of cDNA present in each sample. Data were analyzed
using the comparative difference in cycle number (	CT)
method according to the manufacturer’s instructions. Pro-
tein kinase A inhibitor PKI (Santa Cruz Biotechnology), pro-
tein kinase C inhibitor GF109203X (Tocris), phospholipase
C inhibitor U-73122 (Tocris), calcium channel blocker
nifedipine (Tocris), and -adrenergic receptor antagonist
propranolol (Sigma) were used to define the molecular sig-
naling pathways mediating ISO-induced RLN3 expression in
cardiomyocytes.
Reverse transcription-PCR
Total RNA was isolated from cardiomyocytes, and cDNAs
were synthesized using randomhexamers andMoloneymurine
leukemia virus reverse transcriptase (Invitrogen) (33). The
cDNAs obtained were then amplified by PCR using gene-spe-
cific primers for rat RLN1, RLN3, and RXFP1–3. The primer
sequences were as follows: rat RLN1 (NM_013413), 5-GAG-
CCTTTCGATATGACGTTGA-3 (forward) and 5-GGATC-
TTCTGGTACAACCGATG-3 (reverse); rat RLN3 (NM_
170667), 5-GCTGATGGAGAAGCCAATACA-3 (forward)
and 5-GATCCTAGCACAAGCTGCTAAT-3 (reverse); rat
RXFP1 (NM_201417), 5-GACAACAATGGGTGGTCTC-
TAC-3 (forward) and 5-CCCTGGCTTTAGGAAGGTT-
ATT-3 (reverse); rat RXFP2 (NM_001012475), 5-CGTCC-
AACCCTCTTCTGTATG-3 (forward) and 5-GGACATA-
GCGTGAGTCGTATTC-3 (reverse); and rat RXFP3 (NM_
001008310), 5-GACCATCGTAGTCCTTTCCTTC-3 (for-
ward) and 5-ACACCGGGTGGATAGTAGAT-3 (reverse).
Measurement of rat RLN3 by ELISA
Neonatal rat cardiomyocytes were transduced with Ad-LacZ
and Ad-Nur77 for 48 h as described above. Supernatants were
then collected and concentrated, and the levels of rat RLN3
in the supernatants were quantitated by the rat relaxin 3
(RLN3) ELISA kit supplied by MyBioSource. The assay was
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performed essentially according to the protocol provided by
the manufacturer.
Transient transfection and luciferase assay
The rat RLN3 promoter was amplified by PCR using rat
genomic DNA (Clontech) with primers (forward, 5-GAGAC-
TCGAGACTCCTATAATCCCAGCAC-3; reverse, 5-GAG-
AAAGCTTCGAGGAGAGCCCAGGAA-3) and then cloned
into the luciferase reporter plasmid pGL3-Basic (Promega)
XhoI and HindIII sites. The rat RLN3 promoter deletion
mutant (110 to 70) pGL3-Basic was constructed by using
flowing primers: forward, 5-GAGACTCGAGGGTTGCCAA-
CTGCCTCTCCTC-3; reverse, 5-GAGAAAGCTTCCGAG-
GAGAGCCCAGGAA-3. The rat RLN3 promoter mutant
cloned into pGL3-Basic was constructed using QuikChange II
site-directed mutagenesis kit (Agilent Technologies), using the
following PCR primers: 5-GGCAAGGAGATGGTAAAAAT-
CAGGTTGCCAAC-3 and 5-GTTGGCAACCTGATTTTT-
ACCATCTCCTTGCC-3. NRVMs seeded in 12-well plates
were transfected with 200 ng of pGL3-RLN3 promoter lucifer-
ase reporter and 20 ng of pCMV-R.Luc transfection control
plasmid with increasing concentrations of Nur77 expression
vector using LipofectamineTM LTX (Invitrogen) transfec-
tion reagent. 36 h after transfection, cells were then treated
with or without 10 M ISO for 24 h and then directly lysed in
the lysis buffer (Promega). 20 l of the cell lysates were
assayed for luciferase activity with a luciferase reporter assay
system (Promega) and determined with a Synergy 2 multi-
mode microplate reader (Bio-Tek) according to the manufa-
cturer’s instructions.
ChIP assays
ChIP assays were performed using a ChIP assay kit (Upstate)
according to the instructions of the manufacturer. Soluble
chromatin was prepared from neonatal rat cardiomyocytes
stimulated with ISO (10 M) for 3 h or cells transduced with
either Ad-LacZ or Ad-Nur77 (MOI  100) for 48 h. DNA-
bound Nur77 subunit was immunoprecipitated by incubating
with antibody directed against Nur77 or normal IgG (5g; Cell
Signaling) overnight at 4 °C with rotation. After reversal of
cross-links and digestion of bound proteins, the recovered
DNA was quantified by PCR amplified using primer pairs that
cover NBRE in the rat RLN3 promoter as follows: sense, 5-
GGAAGATGACAGGGAGCTG-3; antisense, 5-CTGACC-
TGGGTTATCTTCTGAG-3.
TUNEL staining and cell death ELISA
A TUNEL assay was performed using the In Situ Cell Death
Detection kit (Roche Applied Science) as we described previ-
ously. Briefly, after drug treatment, cardiomyocytes were fixed
with 4%paraformaldehyde solution for 30min at room temper-
ature. After washing with PBS, cells were incubated with 0.3%
H2O2 for 30 min at room temperature to block endogenous
peroxidase activity. After incubation in the TUNEL reaction
mixture for 60 min, the cells were visualized by microscopy
(Nikon, Tokyo, Japan). Cell death ELISA was performed by
using Cell Death Detection ELISA kit (Roche Applied Science).
Briefly, the cytoplasmic fractions were added to the 96-well
ELISA plates precoated with the antihistone mAb and incu-
bated for 90 min at room temperature. After washing, bound
nucleosomes were detected by the addition of anti-DNA per-
oxidase mAb and reacted for 60 min at room temperature.
After the addition of substrate, absorbance was read with an
ELISA reader at 405 nm.
Statistical analyses
All experiments were performed at least three times. All sta-
tistical analysis was performed using the SPSS statistical analy-
sis program (version 17.0), and graphs were generated using
GraphPad Prism software (version 5.0.1). All data are presented
as mean
 S.D. For relative data analysis, the mean value of the
control group is defined as 1 or as 100%. Differences between
two groups were compared with the unpaired Student’s t test.
Differences betweenmultiple groups were compared with one-
way analysis of variance. A p value 0.05 was considered to be
significant.
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